• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>RSC Advances >The tetrameric peptide LfcinB (20–25)4 derived from bovine lactoferricin induces apoptosis in the MCF-7 breast cancer cell line
【24h】

The tetrameric peptide LfcinB (20–25)4 derived from bovine lactoferricin induces apoptosis in the MCF-7 breast cancer cell line

机译：源自牛乳铁蛋白的四聚体肽LfcinB（20–25）4诱导MCF-7乳腺癌细胞系凋亡

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The cytotoxic effect of the tetrameric peptide LfcinB (20–25) _(4) against breast cancer cell line ATCC? HTB-22? (MCF-7) was evaluated. The tetrameric peptide exhibited a concentration-dependent cytotoxic effect against MCF-7 cancer cells. The peptide at 22 μM had the maximum cytotoxic effect against MCF-7 cancer cells, reducing their cell viability to ～20%. The cytotoxic effect of the tetrameric peptide against MCF-7 cells was sustained for 24 hours. Furthermore, the tetrameric peptide did not exhibit a significant cytotoxic effect against the non-tumorogenic trophoblastic cell line, which confirms their selectivity for breast cancer cell lines. The MCF-7 cells treated at 12.2 μM for 1 h exhibited morphological changes characteristic of apoptosis, such as rounded forms and cellular shrinkage. Furthermore, this peptide induces severe cellular damage to MCF-7 cells, mitochondrial membrane depolarization, and increase of cytoplasmic calcium concentration. Our results suggest that it has a significant selective cytotoxic effect against MCF-7 cells, which may be mainly associated with the apoptotic pathway. This peptide, which contains the RRWQWR motif, could be considered to be a promising candidate for developing therapeutic agents for the treatment of breast cancer.
机译：四聚体肽LfcinB（20-25）_（4）对乳腺癌细胞系ATCC的细胞毒性作用？ HTB-22？ （MCF-7）被评估。四聚体肽对MCF-7癌细胞表现出浓度依赖性的细胞毒性作用。该肽在22μM时对MCF-7癌细胞具有最大的细胞毒性作用，将其细胞活力降低至约20％。四聚体肽对MCF-7细胞的细胞毒性作用持续24小时。此外，四聚体肽对非肿瘤滋养细胞系没有显着的细胞毒性作用，这证实了它们对乳腺癌细胞系的选择性。以12.2μM处理1 h的MCF-7细胞表现出凋亡的形态学特征，例如圆形和细胞萎缩。此外，该肽诱导了对MCF-7细胞的严重细胞损伤，线粒体膜去极化和细胞质钙浓度的增加。我们的结果表明，它对MCF-7细胞具有明显的选择性细胞毒性作用，这可能主要与细胞凋亡途径有关。含有RRWQWR基序的这种肽可以被认为是开发治疗乳腺癌的治疗剂的有希望的候选物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号